{"id":508,"date":"2008-12-09T14:02:26","date_gmt":"2008-12-09T18:02:26","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/hematology\/?p=508"},"modified":"2009-01-12T13:07:01","modified_gmt":"2009-01-12T17:07:01","slug":"ash-presentations","status":"publish","type":"post","link":"https:\/\/www.bumc.bu.edu\/hematology\/2008\/12\/09\/ash-presentations\/","title":{"rendered":"December 2008: Presentations at the American Society of Hematology Conference"},"content":{"rendered":"<p><strong>Beth M. Hovey, PhD Candidate<\/strong> in Dr. David Seldin&#8217;s lab presented a poster on &#8220;siRNA, A Potential Therapy for AL Amyloidosis.&#8221;<\/p>\n<p><strong>Dr. Vaishali Sanchorawala<\/strong> presented a talk titled,\u00a0&#8220;Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem cell Transplantation: Trend over the Past 14 year at a Single Institution.&#8221;<\/p>\n<p>The Name of the session\u00a0was, &#8220;Clinical Transplantation &#8211; transplantation regimen toxicities and engraftment.&#8221;<\/p>\n<p><strong>Dr. Michael Rosenzweig<\/strong> presented, &#8220;Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis:\u00a0 A &#8220;Melphalan Recall&#8221; Reaction.&#8221;<\/p>\n<p><strong>Dr. Zhao Lu<\/strong> presented a poster titled, &#8220;<span style=\"font-size: x-small\">A Head-to-Head Comparison Between Cyclophosphamide and Ontak in Reducing the Influence of Tregs on Self (Tumor) Peptide-Specific CTL Responses.&#8221;<\/span><\/p>\n<p><a href=\"http:\/\/www.hematology.org\/\" target=\"_blank\">Click here for more information about the American Society of Hematology.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beth M. Hovey, PhD Candidate in Dr. David Seldin&#8217;s lab presented a poster on &#8220;siRNA, A Potential Therapy for AL Amyloidosis.&#8221; Dr. Vaishali Sanchorawala presented a talk titled,\u00a0&#8220;Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem cell Transplantation: Trend over the Past 14 year at a Single Institution.&#8221; The Name of the [&hellip;]<\/p>\n","protected":false},"author":1099,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[403],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/posts\/508"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/users\/1099"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/comments?post=508"}],"version-history":[{"count":6,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/posts\/508\/revisions"}],"predecessor-version":[{"id":512,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/posts\/508\/revisions\/512"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/media?parent=508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/categories?post=508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/tags?post=508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}